A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 30 Aug 2024
At a glance
- Drugs BMS 986460 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 10 Oct 2023 Status changed from not yet recruiting to recruiting.
- 10 Oct 2023 New trial record